Charles Sehlhorst is a pharmacist who is specialized in Oncology in Lima, Ohio. Patients can reach him at 803 W Market St, Suite 200, Lima or contact him on 419-996-2752. Active license number of Charles Sehlhorst is 03221296 for Oncology in Ohio. Charles Sehlhorst is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Charles Sehlhorst speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Charles Sehlhorst
Specialization:
Oncology
Credentials:
RPH
Gender:
Male
Location:
803 W Market St, Suite 200, Lima, Ohio, 45805-2796
Phone:
419-996-2752
Fax:
419-996-5040
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Charles Sehlhorst are as mentioned below.
NPI Number:
1457709719
NPI Enumeration Date:
27 May, 2016
NPI Last Update On:
27 May, 2016
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Charles Sehlhorst are as mentioned below.
Specialization
License Number
State
Status
Oncology
03221296
Ohio
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
803 W Market St, Suite 200 Lima, Ohio
Zip:
45805-2796
Phone Number:
419-996-2752
Fax Number:
419-996-5040
Patients can reach Charles Sehlhorst at 803 W Market St, Suite 200, Lima, Ohio or can call on phone at 419-996-2752.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.